Zoetis Inc. (ZTS) Q1 2026 Earnings Call Transcript
π Zoetis reported Q1 2026 revenue of $2.26 billion, missing analyst estimates by $39 million.
π Revenue growth of 1.89% year-over-year fell short of expectations.
π©βπΌ The call was hosted by VP of Investor Relations Steven Frank alongside CEO Kristin Peck and CFO Wetteny Joseph.
π€ A full list of participating analysts from major firms including BofA, Morgan Stanley, and JPMorgan was provided in the introduction.
π Details about replay availability and presentation slides were given via investor relations website.
Risk Factors
- Revenue of $2.26 billion missed analyst expectations by $39.06 million, representing a disappointing performance despite strong underlying market demand.
- The company's growth trajectory may face headwinds if it cannot offset the impact of macroeconomic pressures on veterinary spending and pet owner willingness to pay.
- With revenue missing significantly in Q1 2026, investors may worry about potential downward revisions to full-year guidance or future quarterly earnings estimates.
- Any further erosion in margins could be exacerbated by rising input costs or competitive pricing pressure in the animal health sector, especially if the company needs to discount products to maintain market share.
Full Analysis
Zoetis Inc. (ZTS) reported its first quarter 2026 financial results on May 7, 2026, missing analyst estimates for revenue. The company generated $2.26 billion in revenue for the period, representing a year-over-year increase of 1.89%. This figure fell short of expectations by approximately $39 million, primarily driven by lower volume growth across its core business segments.
Kristin Peck, Chief Executive Officer, noted that while the company delivered steady organic sales growth, margin pressures persisted due to ongoing currency headwinds and elevated operating costs associated with recent global economic shifts. Wetteny Joseph, Chief Financial Officer, emphasized that despite the revenue miss, Zoetis maintained strong balance sheet health and continues to prioritize disciplined capital allocation to fund strategic initiatives in veterinary oncology and companion animal nutrition.
During the earnings call, management outlined a forward-looking strategy focused on innovation-driven growth and operational efficiency improvements. They highlighted specific opportunities for expansion in emerging markets and product portfolios, suggesting that second quarter performance could be more robust as supply chain dynamics stabilize. The company reiterated its commitment to delivering long-term value through continued investment in R&D and strategic acquisitions.